SI1848458T1 - Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov - Google Patents

Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov

Info

Publication number
SI1848458T1
SI1848458T1 SI200630466T SI200630466T SI1848458T1 SI 1848458 T1 SI1848458 T1 SI 1848458T1 SI 200630466 T SI200630466 T SI 200630466T SI 200630466 T SI200630466 T SI 200630466T SI 1848458 T1 SI1848458 T1 SI 1848458T1
Authority
SI
Slovenia
Prior art keywords
protein
separation
activated polymers
polypeptide multimers
polypeptide
Prior art date
Application number
SI200630466T
Other languages
English (en)
Inventor
Andreas Wolf
Patrick Hoffmann
Nee Henckel Julia Hepp
Tobias Raum
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of SI1848458T1 publication Critical patent/SI1848458T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
SI200630466T 2005-02-16 2006-02-15 Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov SI1848458T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003332 2005-02-16
EP06706962A EP1848458B1 (en) 2005-02-16 2006-02-15 Use of activated polymers for separation of protein and polypeptide multimers

Publications (1)

Publication Number Publication Date
SI1848458T1 true SI1848458T1 (sl) 2010-01-29

Family

ID=36168573

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630466T SI1848458T1 (sl) 2005-02-16 2006-02-15 Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov

Country Status (12)

Country Link
US (1) US20080312411A1 (sl)
EP (1) EP1848458B1 (sl)
JP (1) JP2008530163A (sl)
AT (1) ATE447414T1 (sl)
AU (2) AU2006215823A1 (sl)
CA (1) CA2594666A1 (sl)
DE (1) DE602006010176D1 (sl)
DK (1) DK1848458T3 (sl)
ES (1) ES2335304T3 (sl)
HR (1) HRP20090594T1 (sl)
SI (1) SI1848458T1 (sl)
WO (1) WO2006087178A1 (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331139B1 (en) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
JP6141444B2 (ja) 2012-12-14 2017-06-07 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環式モルフィナンおよびこれらの使用
CA2894971C (en) 2012-12-14 2018-06-26 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
EP2931724B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Pyridonemorphinan analogs and biological activity on opioid receptors
JP6159416B2 (ja) 2012-12-28 2017-07-05 パーデュー、ファーマ、リミテッド、パートナーシップ 7,8−環式モルフィナン類似体
EP2941431B1 (en) 2012-12-28 2017-10-25 Purdue Pharma L.P. Substituted morphinans and the use thereof
ES2748803T3 (es) 2012-12-31 2020-03-18 Rhodes Tech Procedimiento para preparar 6,14-etenomorfinanos sustituidos en 7, 6,14-etanomorfinanos sustituidos en 7
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
US11124505B2 (en) 2016-12-23 2021-09-21 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
US11845759B2 (en) 2018-02-23 2023-12-19 Rhodes Technologies Opioid compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
ES2367891T3 (es) * 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
KR20040069980A (ko) * 2001-06-22 2004-08-06 파마시아 코포레이션 화학적으로 변형된 프로게니포이에틴 접합체

Also Published As

Publication number Publication date
JP2008530163A (ja) 2008-08-07
HRP20090594T1 (hr) 2009-12-31
WO2006087178A1 (en) 2006-08-24
ATE447414T1 (de) 2009-11-15
US20080312411A1 (en) 2008-12-18
AU2007237199A1 (en) 2008-01-17
EP1848458A1 (en) 2007-10-31
CA2594666A1 (en) 2006-08-24
DE602006010176D1 (de) 2009-12-17
EP1848458B1 (en) 2009-11-04
ES2335304T3 (es) 2010-03-24
AU2006215823A1 (en) 2006-08-24
DK1848458T3 (da) 2010-02-01

Similar Documents

Publication Publication Date Title
SI1848458T1 (sl) Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov
WO2007104062A3 (en) Compositions and methods based on peptide binding profiling
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
ES2322882B1 (es) Peptidos inhibidores de la exocitosis neuronal.
EP2617431A3 (en) Polypeptide inhibitors of HSP27 kinase and uses therefor
WO2011047087A3 (en) Protein detection via nanoreporters
WO2014026136A3 (en) Protease-resistant systems for polypeptide display and methods of making and using thereof
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
WO2008157378A3 (en) Rage fusion proteins
CL2007003303A1 (es) Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
PL1909602T3 (pl) Systemy i metody stosowane do oddzielania białek od tkanki łącznej
DE602006011229D1 (de) System zur Stromsymmetrierung
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
AU2009312751A8 (en) A screening assay for insecticides
DE602006011497D1 (de) Empfang von an mehrere einrichtungen adressiertem audiovisuellem inhalt
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
IL223077A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
WO2008002820A3 (en) Substituted benzyl amine compounds
WO2007101146A3 (en) Selective vpac2 receptor peptide agonists
WO2007133828A3 (en) Selective vpac2 receptor peptide agonists
CY1114618T1 (el) Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη
WO2009005718A8 (en) Polypeptide microparticles having sustained release characteristics, methods and uses
EP2101804B8 (en) Pro-angiogenic peptides